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Abstract The deregulation of Wnt signaling has recently
emerged as one of the drivers of head and neck cancers. This
is frequently related to the methylation of several antagonists
of this pathway. This study aimed at the assessment of the
profile of methylation of Wnt pathway antagonists and the
determination of the prognostic value of the methylation of
selected genes in oral carcinomas. The methylation of
DACH1, DKK1, LKB1, PPP2R2B, RUNX3, SFRP2, and
WIF-1 was analyzed in 16 oral squamous cell carcinoma cell
lines using the methylation-specific polymerase chain reac-
tion. The methylation of selected genes was further analyzed
in tumor sections from 43 primary oral carcinoma patients.
The analysis of oral carcinoma cell lines showed very frequent
methylation of SFRP2 and WIF-1 and also a less frequent
methylation of DACH1 and DKK1. On the other hand,
RUNX3 was methylated only in one cell line, while LKB1
and PPP2R2B were not methylated in any of the cell lines.
The biallelic methylation of DKK1 correlated with the low
level of expression of this gene. Further evaluation of the
methylation ofDACH1, DKK1, andWIF1 in a clinical patient
group confirmed the frequent methylation of WIF1 and inter-
mediate or low frequency ofmethylation ofDACH1 orDKK1,
respectively. Importantly, the methylation ofWIF-1 correlated
with shorter survival in oral cancer patients. Overall, the
methylation of the antagonists of Wnt pathway is frequently
detected in oral squamous cell carcinomas. Themethylation of
WIF1 may be considered a prognostic marker in oral cancers.
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Abbreviations
HNSCC Head and neck squamous cell carcinoma
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Introduction
Oral and oropharyngeal squamous cell carcinoma (OSCC) is a
common cancer of the head and neck region, and it ranks as
the eighth most prevalent cancer among males in the USA [1].
The overall 5-year survival rates are around 50–60 %, and
despite the growing understanding of the molecular pathogen-
esis of head and neck squamous cell carcinomas (HNSCC),
therapy outcomes remain unaltered what is explained by a
relatively frequent rate of tumor relapse or the appearance of
metastases [2]. The improvement of treatment outcomes may
be facilitated by the discovery of new diagnostic markers.
Among molecular markers, epigenetic biomarkers based on
the analysis of DNAmethylation profiles have already proven
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to be useful in both the detection and the prognostication of
cancer [3].
The Wnt/β-catenin signaling pathway serves for the regu-
lation of cell proliferation, migration, and apoptosis.When the
pathway is in the resting state, the chief protein that serves for
signal transduction–β-catenin is phosphorylated by an inhib-
itory complex which comprises of glycogen synthase kinase
3β (GSK-3β), casein kinase 1α, adenomatous polyposis coli
(APC), and Axin. Phosphorylated β-catenin is immediately
degraded via the ubiquitin-proteasome pathway, and thus, the
cytoplasmic pool of β-catenin is kept at a very low level.
During pathway activation, the binding of Wnt ligands to
Frizzled receptors activates Dishevelled, which inhibits the
activity of GSK-3β and blocks the degradation of β-catenin.
This enables the accumulation of β-catenin in the cytoplasm
and its subsequent translocation to the nucleus where it binds
the TCF/LEF family of transcription factors and stimulates the
expression of genes which enhance cell cycle and cell migra-
tion, such as CCND1, MYC, MMP-7, or survivin [4].
Mutations in the genes coding for proteins in the Wnt
pathway are rare in HNSCC, and thus, this pathway was not
believed to be significant for the pathogenesis of head and
neck carcinomas [5–8]. However, recent investigations indi-
cate that the hyperactivation of the pathway may result from a
different mechanism which is based on the aberrant hyperme-
thylation of the negative regulators of Wnt pathway. The
genes which encode the extracellular antagonists of Wnt
ligands or Frizzled/LRP receptors, such as SFRP1-5, WIF1,
or DKK1-3, are frequently silenced in HNSCC cells through
the methylation of their promoter regions. Also, the function
of the intracellular negative Wnt regulators such as DACH1,
PPP2R2B, or RUNX3 may be lost due to the hypermethyla-
tion of their gene promoters [7, 9–11]. It has been also report-
ed that the expression of Wnt ligands, Frizzled receptors, and
Dishevelled as well asβ-catenin is increased in head and neck
(HN) carcinoma cells [7, 12–15]. Moreover, the appearance of
nuclear β-catenin and the enhancement of the expression of
β-catenin target genes, such as MYC, CCND1, MMP-7, or
survivin are often observed in HNSCC cancer cells. Impor-
tantly, such changes seem to be cancer-specific since nuclear
β-catenin was not detected in normal oral mucosa in contrast
to oral leukoplakia. Additionally, dysplastic leukoplakia
showed stronger nuclear accumulation of β-catenin than
non-dysplastic leukoplakia [16]. Another study showed that
the upregulated proliferation of basaloid cells in oral epithelial
dysplasia may be caused by enhanced Wnt signaling [17].
Accumulating evidence suggests that the activation of Wnt
signaling escalates with the progression of head and neck
cancers. Elevated expression of β-catenin correlated with
shorter survival of patients with oral carcinomas [13]. In line
with this observation, the knockdown of β-catenin reduced
the growth of HN cancer cells and tumors [18, 19]. Moreover,
the expression ofβ-catenin was higher in poorly differentiated
tumors than in moderate and well-differentiated tumors. In-
deed, β-catenin may inhibit the differentiation of
keratinocytes through the upregulation of Myc [13]. Another
study showed that the hyperactivation ofβ-catenin affects cell
morphology and cell adhesion leading to the higher capacity
of cells for invasion and migration driven i.a. by β-catenin-
induced activation of MMP-7 expression [20]. This indicates
that the cytoplasmic and nuclear accumulation of β-catenin
contributes to epithelial to mesenchymal transition in HN
carcinoma cells and, thus, may be significantly associated
with local recurrence and lymph node metastasis. All these
facts underscore the biological importance of the aberrations
in Wnt signaling in the pathogenesis of HNSCC and indicate
the possible prognostic significance of changes in Wnt path-
way activity in disease diagnostics.
The aim of the present study was to assess the frequency of
gene promoter methylation of Wnt pathway antagonists
(DACH1, DKK1, LKB1, PPP2R2B, RUNX3, SFRP2, and
WIF-1) in oropharyngeal squamous cell carcinoma cell lines
and establish the diagnostic potential of the most promising
genes in respect to correlation with important clinicopatho-
logic data such as tumor recurrence or disease-free survival in
a group of oropharyngeal cancer patients. We indicate that the
analysis of the methylation of the promoter region of WIF-1
constitutes the most promising prognostic biomarker in OSCC
patients.
Materials and methods
Oral cancer cell lines
Sixteen cell lines derived from oral squamous cell carcinoma
patients at the University of Turku, Finland were used in this
study. Table 1 presents the characteristics of the original
material taken to establish each of the cell lines.
Patients
Forty-three patients with primary oral squamous cell carcino-
ma who were primarily treated surgically at the Department of
Otolaryngology and Clinical Oncology, Poznań University of
Medical Sciences between 2008 and 2012 were enrolled for
the study. Clinical data are collected in Table 2. All the
samples underwent histopathological examination and were
verified to contain at least 80 % of cancer cells. The follow-up
observation in most cases covered at least 3 years following
surgery. Thirteen patients died of cancer during follow-up.
Seven patients were lost from ongoing observation after
3 years of follow-up. Moreover, only incomplete observations
were available for another six patients whose follow-up ob-
servation lasted for less than 3 years (2–24 months). Follow-
up information was lacking in the case of two patients. The
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study was approved by the Poznan University of Medical
Sciences ethics committee (approval no. 1199/08).
Methylation-specific PCR
DNA was extracted from samples using a standard phenol/
chloroform protocol. The methylation status of DACH1,
DKK1, LKB1, PPP2R2B, RUNX3, SFRP2, and WIF-1 was
assessed using the methylation-specific polymerase chain re-
action (MSP) [21], as previously described [9]. The primers
and reaction conditions for MSP were chosen based on pre-
viously published data [7, 22–25]. All the primers were ob-
tained from Oligo.pl (Warsaw, Poland). DNA extracted from
the lymphocytes of healthy blood donors and a completely
methylated human DNA (Fermentas, Burlington, Canada)
were used as the negative and positive MSP control,
respectively. Genomic DNA samples derived from early
passage primary culture of human tracheal epithelial cells
and human oral keratinocytes (ScienCell Research
Laboratories, Carlsbad, CA, USA) were used as normal
controls for comparison. Amplification products were
resolved on 2 % agarose gels and visualized under UV light
illumination.
Quantitative PCR
Total RNAwas extracted by standard phenol/guanidine thio-
cyanate extraction and subjected to reverse transcription using
the RevertAid Kit (Fermentas). Quantitative real-time PCR
was performed using the HOT FIREPol Eva Green qPCRMix
(Solis BioDyne, Tartu, Estonia) and a Chromo4 thermal cycler
(BioRad Laboratories, Hercules, CA, USA). The amplifica-
tion protocol started with a 15-min enzyme activation at
95 °C, followed by 40 cycles of 95 °C for 20 s, 56 °C for
20 s, and 72 °C for 40 s and the final elongation at 72 °C for
5 min. The melting curve analysis was used for the verifica-
tion of the lack of non-specific products. Measurements were
Table 1 The characteristics of the patients and tumors that were taken to establish the analyzed laryngeal squamous cell carcinoma cell lines
Cell line Sex Age (years) Primary tumor location TNM classification Specimen site Type of lesion Histological grade
UT-SCC-10 M 62 SCC linguae T1N0M0 Tongue pri G2
UT-SCC-16A F 77 SCC linguae T3N0M0 Tongue pri G3
UT-SCC-16B F 77 SCC linguae T3N0M0 Neck met G3
UT-SCC-20A F 58 Floor of mouth T1N0M0 Floor of mouth pri (per) G2
UT-SCC-20B F 58 Floor of mouth Floor of mouth resid G2
UT-SCC-24A M 41 SCC linguae T2N0M0 Tongue pri G2
UT-SCC-24B M 41 SCC linguae Neck met (per) G2
UT-SCC-28 F 58 Floor of mouth T2N0M0 Floor of mouth pri (per) G1
UT-SCC-36 M 46 Floor of mouth T4N1M0 Floor of mouth pri G3
UT-SCC-45 M 76 Floor of mouth T3N1M0 Floor of mouth pri G3
UT-SCC-47 M 78 Floor of mouth T2N0M0 Floor of mouth pri G3
UT-SCC-56 M 62 Floor of mouth TxN2M0 Floor of mouth rec G2-G3
UT-SCC-85 M 55 SCC marginum linguae T3N0M0 Tongue-floor of mouth rec G2
UT-SCC-90 M 35 SCC linguae T1N0M0 Floor of mouth rec/met G2
UT-SCC-100 M 70 SCC gingiva mandibularis rT3 Mucosae bucchae rec G3
UT-SCC-104 M 80 SCC plicae ventricularis T1N2AM0 Neck met G2
M male, F female, SCC squamous cell carcinoma, pri primary tumor, per persistent, met metastasis, rec recurrent tumor
Table 2 Patient and tumor characteristics












Histological grade G1 6
G2 33
G3 4
Tumor localization Tonsils 13
Tongue 7
Tongue and floor of the mouth 14
Palate 2
Lips 1
Base of the tongue and tonsils 6
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normalized for the expression of TATA box binding protein
(TBP). Primer sequences are listed in Table 3.
Statistical analysis
The correlation between clinicopathologic features and gene
methylation was assessed with chi-square or Fisher’s exact
test and F-Cox test (p≤0.05) using STATISTICA 10.
Results
In the first stage, 16 oral squamous cell carcinoma cell lines
were screened for the methylation of DACH1, DKK1, LKB1,
PPP2R2B, RUNX3, SFRP2, and WIF-1 using methylation-
specific PCR.We detected very frequent methylation ofWIF1
(93.7 %) and SFRP2 (81.2 %) and moderately frequent meth-
ylation ofDKK1 (37.5 %) andDACH1 (31.2 %). RUNX3was
found methylated in only one cell line (6.25 %), and the other
genes (LKB1 and PPP2R2B) were not methylated in any of
the cell lines. In order to assess whether the observed profile of
methylation changes is specific for cancer cells, we analyzed
the status of methylation of all the genes in normal cells of the
upper aero-digestive tract—tracheal epithelial cells and oral
keratinocytes. None of the genes was methylated in the geno-
mic DNA derived from normal cells, except for SFRP2, which
showed partial methylation in tracheal epithelial cells. There-
fore, SFRP2 was excluded from further analysis.
Next, we analyzed whether there is any association be-
tween the status of methylation of gene promoters ofDACH1,
DKK1, and WIF-1 and their level of expression in the cell
lines (Fig. 1). In the case of DACH1, we found similar levels
of the transcript in all the cell lines, irrespective of gene
methylation status. This was however not surprising since,
when present, usually partial (probably monoallelic) methyl-
ation was observed for this gene. On the other hand, complete
gene silencing (methylation of both alleles) was usually ob-
served in the cell lines positive for DKK1 methylation. This
biallelic methylation of DKK1 was accompanied by low tran-
script level when compared with cell lines showing the lack of
methylation of this gene. As expected, the expression ofWIF1
was almost undetectable in the analyzed cell lines due to
heavy methylation of the gene promoter.
Based on these results, we identified DACH1, DKK1, and
WIF-1 as potential epimarkers in OSCC and further analyzed
their methylation in a group of oral squamous cell carcinoma
patients. We detected frequent methylation ofWIF-1 (63.9 %)
and moderately frequent methylation ofDACH1 (35.9 %). On
the other hand, only rare cases of methylation of DKK1
(7.1 %) were observed. One fifth of the patients did not show
the methylation of any of the tested genes. Usually, only one
of the genes was methylated in the patient’s tumor DNA
sample. Another one fifth of the patients showed the methyl-
ation of two genes (mostly the co-methylation ofDACH1 and
WIF1). Only one patient showed the methylation of all three
genes.
The methylation of the analyzed genes did not correlate
with either tumor stage (T), nodal involvement (N), tumor
localization, or local recurrence. The methylation of WIF1
significantly correlated (p=0.036) with shorter survival
(Fig. 2). Also, the methylation of DKK1 correlated with
histological grade (p=0.002). However, both observations
should be interpreted with caution because of the relatively
low number of subjects enrolled in the study.
Discussion
The number of new cases and the effectiveness of therapy of
head and neck squamous cell carcinomas has remained rela-
tively unaltered over the last decade. Mean 5-year survival
rates around 60 % can be reached when surgery and/or radio-
therapy are applied as standard treatment options [1]. The
effectiveness is higher in patients with low-grade tumor and
dramatically decreases in advanced cancer. Despite the grow-
ing understanding of the molecular changes that take place at
different stages of the disease, there are still no definite
markers which could be used to identify patients with in-
creased risk of disease progression. So far, there are no ap-
proved markers of the risk of local relapse or other prognostic
tests. The detection of such markers would allow the identifi-
cation of patients showing worse prognosis and a higher risk
of relapse and inform the necessity of application of more
aggressive treatment. On the other hand, treatment options for
such patients are still lacking and this gap needs to be filled in
order to improve therapy outcomes in this group of patients.
The molecular aberrations in the Wnt signaling pathway
have recently emerged as important drivers of HNSCC [6, 16,
17, 20]. This insight can be utilized in both the diagnostics and
treatment of this group of patients. It has been reported that the
activation of this pathway increases with tumor progression
and, indeed, the nuclear accumulation of β-catenin correlated
with shorter survival of patients with oral carcinomas [13].
Table 3 The sequence of starters used in real-time PCR reactions
Primer Sequence Product size
TBP forward 5′GGCACCACTCCACTGTATC 183 bp
TBP reverse 5′GGGATTATATTCGGCGTTTCG
DACH1 forward 5′CAAGTGTCGGACTGGAAC 172 bp
DACH1 reverse 5′GATGTCTCAACTCTGGATGG
DKK1 forward 5′GGAAACCATCACTGAAAGC 154 bp
DKK1 reverse 5′AGCACAACACAATCCTGAG
WIF1 forward 5′ATTCCTGTCAATATCCATTCC 163 bp
WIF1 reverse 5′CAACTGATGCCTTGTGAG
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Since mutations of genes in this pathway are rare in HNSCC,
epigenetic changes seem to be the leading mechanism for the
induction of the hyperactivation of this signaling cascade. In
this regard, frequent hypermethylation of the negative regula-
tors of this pathway (DKK-3, RUNX3, SFRP1, SFRP2,
SFRP4, SFRP5, andWIF1) was observed in oral and oropha-
ryngeal cancers [7, 10, 11, 26–28]. However, the diagnostic
significance of these alterations remains to be elucidated. The
aim of the current study was to assess the profile of methyl-
ation changes of a broader set ofWnt pathway antagonists and
analyze the diagnostic significance of these potential
epimarkers. In the first stage, cell lines derived from OSCC
were screened for the presence of methylation of DACH1,
DKK-1, LKB1, PPP2R2B, RUNX3, SFRP2, andWIF1. Genes
which were frequently methylated in the cell lines and showed
the lack of methylation in DNA samples from normal control
cells were further analyzed in a group of primary OSCC
patients.
The methylation of LKB1 was not present in any of the
tested cell lines.We have previously shown that this gene does
not undergo methylation in laryngeal carcinomas [9]. This is
in agreement with the findings that the downregulation of
LKB1 in head and neck cancers is independent of promoter
methylation [29]. Similarly, PPP2R2B was not methylated in
any of the cell lines. This differentiates oral carcinomas from
laryngeal carcinomas where this gene is very frequently
hypermethylated and shows prognostic significance [9]. It
indicates that other mechanisms are responsible for the de-
crease in the activity of PP2A protein phosphatase complex
which is observed in oral cancers [30].
In the case of RUNX3, we observed its methylation in only
one cell line and thus did not analyze its methylation in
primary carcinoma patients. A similar result was observed in
laryngeal carcinomas [9]. Similarly, the gene was shown to be
hypomethylated in tongue squamous cell carcinoma [31]. In
contrast, others reported the hypermethylation of RUNX3 in
17.8 % OSCC [28]. Moreover, it was detected in 25 % of
tongue carcinomas where it correlated with tumor stage and
lymph node involvement [26]. Another study showed that
RUNX3 was hypermethylated in 70 % OSCC and that the
downregulation of RUNX3 protein correlated with poor dif-
ferentiation [32]. Additionally, another study showed that
RUNX3 was methylated in 60 % of cases of oral dysplasia
Fig. 1 The relationship between
the promoter methylation of
DACH1 and DKK1 and
normalized gene expression
(transcript level). Normalized
level of transcript is expressed as
the ratio calculated from the
formula: Ratio (reference
gene/target gene)=2 Ct (reference)−
Ct (target), where TBP is the
reference gene and either DACH1
or DKK1 is the target gene. Each
bar represents the range of results
obtained for all the samples in the
respective groups with the mean
value marked with the rectangle.
M gene promoter methylation, U








Fig. 2 Disease-free survival estimated byWIF-1methylation in primary
oropharyngeal tumor patients.M patients showingWIF-1methylation, U
patients showing lack of WIF1 methylation
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and 100 % cases of OSCC [11]. There is discrepancy
concerning the actual role of RUNX3 in HNSCC, and some
authors suggest an oncogenic function for this gene [33]. This
needs to be addressed in further functional studies.
Of all the antagonists of Wnt pathway, the methylation of
genes encoding SFRP proteins was most frequently reported
in oral carcinomas. The rate of methylation of SFRP2 widely
ranged (35–90 %) among various studies [7, 10, 11, 27]. We
also detected frequent methylation (81.2 %) of this gene in
OSCC cell lines. However, we observed that this was not fully
cancer-specific. Similarly, the methylation of SFRP1/2/4/5
was also present in normal control samples, although SFRP2
showed the highest cancer specificity among the SFRP genes
[10]. These observations suggest that although SFRPs are
often methylated in OSCC, they might not present good
diagnostic performance due to unsatisfactory specificity.
We report, for the first time, that DACH1 undergoes meth-
ylation in oral squamous cell carcinomas. So far, the methyl-
ation of this gene was detected in colorectal carcinomas where
it correlated with late tumor stage, poor differentiation, and
lymph node metastasis [23]. Recently, DACH1 emerged as an
important tumor suppressor gene [34] and its frequent meth-
ylation in OSCC underscores the potential anti-cancer effects
of epigenetic therapies via suppression of Wnt signaling.
Indeed, it has been shown that the inhibition of Wnt pathway
blocks tumor growth in head and neck cancers [18, 19].
Although the methylation of DKK1 was infrequent in
primary OSCC, it strongly correlated with histological grade.
To our knowledge, the methylation of this gene was not
analyzed in oral cancers although the methylation of another
member of the dickkopf family of genes—DKK3—was pre-
viously reported [10]. However, it was found that the expres-
sion of DKK1 correlated significantly with a low risk of
regional lymph node metastasis and that its knockdown in-
creased the cellular migration and invasiveness in oral cancer
cells [35]. This suggests a potential prognostic significance of
the methylation of this gene in oral carcinomas. Although no
evidence in favor of this hypothesis was found in our study,
this may be attributed to a relatively small cohort of patients
regarding the low frequency of methylation in the group of
primary OSCC patients.
In our study, WIF1 was the most frequently methylated
gene in oral carcinomas. It was previously reported to be
methylated in 18%OSCC [10] and 35% of tongue carcinoma
patients [26]. Moreover, the methylation of this gene can be
considered as a marker of progression of carcinogenesis since
its methylation was observed to be twice more frequent in
OSCC (80 %) than in oral dysplasia (40 %) [11]. Importantly,
we observed that the methylation of the gene correlated with
shorter overall survival of the patients. Although such a cor-
relation was not observed in tongue carcinomas [26], others
reported a similar observation in the case of non-small cell
lung cancer [36].
The results presented in this study corroborate that the
epigenetic abnormalities may frequently affect Wnt signaling
in oral carcinomas. Roughly, 80 % of the patients showed the
methylation of at least one gene. It indicates that this pathway
should be considered a possible therapeutic target in OSCC
apart from the fact that the analysis of promoter methylation of
genes in this cascade presents promising diagnostic
possibilities.
In summary, our current study showed that DACH1,
DKK1, and WIF-1 are methylated in oral and oropharyngeal
squamous cell carcinomas. Moreover, oral cancers are differ-
entiated from laryngeal carcinomas by the lack of methylation
of PPP2R2B. The possible prognostic significance of the
methylation ofDKK1 andWIF1 needs to be further evaluated
in prospective studies.
Conflicts of interest None
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA
Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology
of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22. doi:10.
1038/nrc2982.
3. Paluszczak J, Baer-DubowskaW. Epigenetic diagnostics of cancer—
the application of DNA methylation markers. J Appl Genet.
2006;47(4):365–75. doi:10.1007/bf03194647.
4. Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-
McCaw A, et al. The way Wnt works: components and mechanism.
Growth Factors. 2013;31(1):1–31. doi:10.3109/08977194.2012.
752737.
5. Lea IA, Jackson MA, Li X, Bailey S, Peddada SD, Dunnick JK.
Genetic pathways and mutation profiles of human cancers: site- and
exposure-specific patterns. Carcinogenesis. 2007;28(9):1851–8. doi:
10.1093/carcin/bgm176.
6. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey
DM, et al. Integrative genomic characterization of oral squamous cell
carcinoma identifies frequent somatic drivers. Cancer Discov.
2013;3(7):770–81. doi:10.1158/2159-8290.CD-12-0537.
7. Sogabe Y, Suzuki H, Toyota M, Ogi K, Imai T, Nojima M, et al.
Epigenetic inactivation of SFRP genes in oral squamous cell carci-
noma. Int J Oncol. 2008;32(6):1253–61.
8. Yeh KT, Chang JG, Lin TH, Wang YF, Chang JY, Shih MC, et al.
Correlation between protein expression and epigenetic and mutation
changes of Wnt pathway-related genes in oral cancer. Int J Oncol.
2003;23(4):1001–7.
9. Paluszczak J, Hemmerling D, Kostrzewska-Poczekaj M, Jarmuz-
Szymczak M, Grenman R, Wierzbicka M, et al. Frequent hyperme-
thylation of WNT pathway genes in laryngeal squamous cell carci-
nomas. J Oral Pathol Med off pub Int Assoc Oral Pathol Am Acad
Oral Pathol. 2014. doi:10.1111/jop.12178.
2860 Tumor Biol. (2015) 36:2855–2861
10. Pannone GBP, Santoro A, Franco R, Aquino G, Longo F, Botti G.
WNT pathway in oral cancer: epigenetic inactivation of WNT-inhib-
itors. Oncol Rep. 2010;24:1035–41. doi:10.3892/or_00000952.
11. Towle R, Truong D, Hogg K, Robinson WP, Poh CF, Garnis C.
Global analysis of DNA methylation changes during progression of
oral cancer. Oral Oncol. 2013;49(11):1033–42. doi:10.1016/j.
oraloncology.2013.08.005.
12. Diaz Prado SM, Medina Villaamil V, Aparicio Gallego G, Blanco
Calvo M, Lopez Cedrun JL, Sironvalle Soliva S, et al. Expression of
Wnt gene family and frizzled receptors in head and neck squamous
cell carcinomas. VirchowsArch Int J pathol. 2009;455(1):67–75. doi:
10.1007/s00428-009-0793-z.
13. Ravindran G, Devaraj H. Aberrant expression of beta-catenin and its
association with DeltaNp63, Notch-1, and clinicopathological factors
in oral squamous cell carcinoma. Clin Oral Investig. 2012;16(4):
1275–88. doi:10.1007/s00784-011-0605-0.
14. Leethanakul C, Patel V, Gillespie J, Pallente M, Ensley JF,
Koontongkaew S, et al. Distinct pattern of expression of differenti-
ation and growth-related genes in squamous cell carcinomas of the
head and neck revealed by the use of laser capture microdissection
and cDNA arrays. Oncogene. 2000;19(28):3220–4. doi:10.1038/sj.
onc.1203703.
15. Rhee CS, Sen M, Lu D, Wu C, Leoni L, Rubin J, et al. Wnt and
frizzled receptors as potential targets for immunotherapy in head and
neck squamous cell carcinomas. Oncogene. 2002;21(43):6598–605.
doi:10.1038/sj.onc.1205920.
16. Ishida K, Ito S,WadaN, Deguchi H, Hata T, HosodaM, et al. Nuclear
localization of beta-catenin involved in precancerous change in oral
leukoplakia. Mol Cancer. 2007;6:62. doi:10.1186/1476-4598-6-62.
17. Alvarado CG, Maruyama S, Cheng J, Ida-Yonemochi H, Kobayashi
T, Yamazaki M, et al. Nuclear translocation of beta-catenin synchro-
nized with loss of E-cadherin in oral epithelial dysplasia with a
characteristic two-phase appearance. Histopathology. 2011;59(2):
283–91. doi:10.1111/j.1365-2559.2011.03929.x.
18. Duan Y, Fan M. Lentivirus-mediated gene silencing of beta-catenin
inhibits growth of human tongue cancer cells. J Oral Pathol Med Off
Pub Int Assoc Oral Pathol AmAcad Oral Pathol. 2011;40(8):643–50.
doi:10.1111/j.1600-0714.2011.01007.x.
19. Chang HW, Lee YS, Nam HY, Han MW, Kim HJ, Moon SY, et al.
Knockdown of beta-catenin controls both apoptotic and autophagic
cell death through LKB1/AMPK signaling in head and neck squa-
mous cell carcinoma cell lines. Cell Signal. 2013;25(4):839–47. doi:
10.1016/j.cellsig.2012.12.020.
20. Iwai SYA, Harada C, Hamada M, Katagiri W, Nakazawa M, Yura Y.
Involvement of the Wnt-β-catenin pathway in invasion and migra-
tion of oral squamous carcinoma cells. Int J Oncol. 2010;37(5):1095–
103. doi:10.3892/ijo_00000761.
21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB.
Methylation-specific PCR: a novel PCR assay for methylation status
of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.
22. Esteller M, Avizienyte E, Corn PG, Lothe RA, Baylin SB, Aaltonen
LA, et al. Epigenetic inactivation of LKB1 in primary tumors asso-
ciated with the Peutz-Jeghers syndrome. Oncogene. 2000;19(1):164–
8. doi:10.1038/sj.onc.1203227.
23. Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, et al.
Epigenetic regulation of DACH1, a novel Wnt signaling component
in colorectal cancer. Epigenetics. 2013;8(12):1373–83. doi:10.4161/
epi.26781.
24. Tan J, Lee PL, Li Z, Jiang X, Lim YC, Hooi SC, et al. B55beta-
associated PP2A complex controls PDK1-directed myc signaling and
modulates rapamycin sensitivity in colorectal cancer. Cancer Cell.
2010;18(5):459–71. doi:10.1016/j.ccr.2010.10.021.
25. Song HJ, Shim KN, Joo YH, Kim SE, Jung SA, Yoo K. Methylation
of the tumor suppressor gene RUNX3 in human gastric carcinoma.
Gut liver. 2008;2(2):119–25. doi:10.5009/gnl.2008.2.2.119.
26. Supic G, Kozomara R, Jovic N, Zeljic K,Magic Z. Hypermethylation
of RUNX3 but not WIF1 gene and its association with stage and
nodal status of tongue cancers. Oral Dis. 2011;17(8):794–800. doi:
10.1111/j.1601-0825.2011.01838.x.
27. Marsit CJ, McClean MD, Furniss CS, Kelsey KT. Epigenetic inacti-
vation of the SFRP genes is associated with drinking, smoking and
HPV in head and neck squamous cell carcinoma. Int J Cancer J Int
cancer. 2006;119(8):1761–6. doi:10.1002/ijc.22051.
28. de Freitas C-SM, Stur E, Agostini LP, de Podesta JR, de Oliveira JC,
Soares MS, et al. Promoter hypermethylation in primary squamous
cell carcinoma of the oral cavity and oropharynx: a study of a
Brazilian cohort. Mol Biol Rep. 2012;39(12):10111–9. doi:10.1007/
s11033-012-1885-4.
29. Ekizoglu S, Dalay N, Karaman E, Akdeniz D, Ozaydin A, Buyru N.
LKB1 downregulation may be independent of promoter methylation
or FOXO3 expression in head and neck cancer. Transl Res J Lab Clin
Med. 2013;162(2):122–9. doi:10.1016/j.trsl.2013.06.001.
30. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I,
Cha S, et al. CIP2A expression and localization in oral carcinoma and
dysplasia. Cancer Biol Ther. 2010;10(7):694–9. doi:10.4161/cbt.10.
7.12895.
31. Zhang S, Feng XL, Shi L, Gong CJ, He ZJ, Wu HJ, et al. Genome-
wide analysis of DNA methylation in tongue squamous cell carcino-
ma. Oncol Rep. 2013;29(5):1819–26. doi:10.3892/or.2013.2309.
32. Gao F, Huang C, Lin M, Wang Z, Shen J, Zhang H, et al.
Frequent inactivation of RUNX3 by promoter hypermethyla-
tion and protein mislocalization in oral squamous cell carci-
nomas. J Cancer Res Clin Oncol. 2009;135(5):739–47. doi:10.
1007/s00432-008-0508-x.
33. Kudo Y, Tsunematsu T, Takata T. Oncogenic role of RUNX3 in head
and neck cancer. J Cell Biochem. 2011;112(2):387–93. doi:10.1002/
jcb.22967.
34. Popov VM,WuK, Zhou J, PowellMJ,MardonG,Wang C, et al. The
Dachshund gene in development and hormone-responsive tumori-
genesis. Trends Endocrinol Metab TEM. 2010;21(1):41–9. doi:10.
1016/j.tem.2009.08.002.
35. Ogoshi K, Kasamatsu A, Iyoda M, Sakuma K, Yamatoji M,
Sakamoto Y, et al. Dickkopf-1 in human oral cancer. Int J Oncol.
2011;39(2):329–36. doi:10.3892/ijo.2011.1046.
36. Yoshino M, Suzuki M, Tian L, Moriya Y, Hoshino H, Okamoto T,
et al. Promoter hypermethylation of the p16 and Wif-1 genes as an
independent prognostic marker in stage IA non-small cell lung can-
cers. Int J Oncol. 2009;35(5):1201–9.
Tumor Biol. (2015) 36:2855–2861 2861
